{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:01:39Z","timestamp":1778770899728,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T00:00:00Z","timestamp":1713052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T00:00:00Z","timestamp":1713052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Crizotinib, an oral first-generation tyrosine kinase inhibitor (TKI), is superior to systemic chemotherapy for the treatment of non-small cell lung cancer (NSCLC) with positive rearrangement of anaplastic lymphoma kinase (ALK). However, an increased incidence of renal and hepatic cysts has been reported in the patients on crizotinib treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>Here, we describe a case of a 71-year-old Chinese women developed multiple cystic lesions in kidney and liver during crizotinib treatment for the primary and metastatic NSCLC. The renal and hepatic cysts were noted by CT scan 3 months after crizotinib treatment, which were spontaneously and significantly regressed after stopping crizotinib.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Based on literature review and our experience in this case report, we concluded that crizotinib-associated renal cyst (CARCs) has features of malignancy and abscess in radiographic imaging, and thus, pathological confirmation is necessary to avoid inappropriate treatment decision. In addition, to benefit the patients with progress-free survival (PFS), switching from crizotinib to alectinib is recommended for the treatment of NSCLC patients who developed CARCs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13000-024-01480-7","type":"journal-article","created":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T11:01:43Z","timestamp":1713092503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature"],"prefix":"10.1186","volume":"19","author":[{"given":"Peng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JiaHua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,14]]},"reference":[{"issue":"10","key":"1480_CR1","doi-asserted-by":"publisher","first-page":"e0205827","DOI":"10.1371\/journal.pone.0205827","volume":"13","author":"S Lu","year":"2018","unstructured":"Lu S, Yu Y, Fu S, Ren H. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China. PLoS ONE. 2018;13(10):e0205827.","journal-title":"PLoS ONE"},{"issue":"2","key":"1480_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"1480_CR3","doi-asserted-by":"publisher","first-page":"i28","DOI":"10.1093\/annonc\/mdi821","volume":"16","author":"E Felip","year":"2005","unstructured":"Felip E, Stahel RA, Pavlidis N, Force EGT. ESMO Minimum Clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol. 2005;16(Suppl 1):i28\u20139.","journal-title":"Ann Oncol"},{"issue":"4","key":"1480_CR4","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","volume":"16","author":"MG Oser","year":"2015","unstructured":"Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):e165\u201372.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1480_CR5","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1097\/JTO.0b013e3181c4dedb","volume":"4","author":"B Solomon","year":"2009","unstructured":"Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol. 2009;4(12):1450\u20134.","journal-title":"J Thorac Oncol"},{"issue":"7153","key":"1480_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561\u20136.","journal-title":"Nature"},{"issue":"3","key":"1480_CR7","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.3390\/curroncol29030160","volume":"29","author":"AJW Gibson","year":"2022","unstructured":"Gibson AJW, Box A, Cheung WY, Dean ML, Elegbede AA, Hao D, et al. Real-World Management and outcomes of Crizotinib-treated ROS1-Rearranged NSCLC: a retrospective Canadian cohort. Curr Oncol. 2022;29(3):1967\u201382.","journal-title":"Curr Oncol"},{"key":"1480_CR8","doi-asserted-by":"crossref","unstructured":"Wang HS, Liu CY, Hsu SC, Huang SC, Hung TH, Ng KF et al. A single-Institute experience with C-ros Oncogene 1 translocation in Non-small Cell Lung cancers in Taiwan. Int J Mol Sci. 2022;23(10).","DOI":"10.3390\/ijms23105789"},{"issue":"2","key":"1480_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/2278-330X.110506","volume":"2","author":"A Sahu","year":"2013","unstructured":"Sahu A, Prabhash K, Noronha V, Joshi A, Desai S. Crizotinib: a comprehensive review. South Asian J Cancer. 2013;2(2):91\u20137.","journal-title":"South Asian J Cancer"},{"issue":"3","key":"1480_CR10","first-page":"148","volume":"3","author":"HN Mo","year":"2017","unstructured":"Mo HN, Liu P. Targeting MET in cancer therapy. Chronic Dis Transl Med. 2017;3(3):148\u201353.","journal-title":"Chronic Dis Transl Med"},{"issue":"23","key":"1480_CR11","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167\u201377.","journal-title":"N Engl J Med"},{"issue":"3","key":"1480_CR12","doi-asserted-by":"publisher","first-page":"e000219","DOI":"10.1136\/esmoopen-2017-000219","volume":"2","author":"F Blackhall","year":"2017","unstructured":"Blackhall F, Ross Camidge D, Shaw AT, Soria JC, Solomon BJ, Mok T, et al. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced\/metastatic ALK-positive non-small-cell lung cancer. ESMO Open. 2017;2(3):e000219.","journal-title":"ESMO Open"},{"issue":"1","key":"1480_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ekir.2016.09.055","volume":"2","author":"KD Jhaveri","year":"2017","unstructured":"Jhaveri KD, Wanchoo R, Sakhiya V, Ross DW, Fishbane S. Adverse renal effects of Novel Molecular Oncologic targeted therapies: a narrative review. Kidney Int Rep. 2017;2(1):108\u201323.","journal-title":"Kidney Int Rep"},{"issue":"11","key":"1480_CR14","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1097\/JTO.0000000000000326","volume":"9","author":"YT Lin","year":"2014","unstructured":"Lin YT, Wang YF, Yang JC, Yu CJ, Wu SG, Shih JY, et al. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2014;9(11):1720\u20135.","journal-title":"J Thorac Oncol"},{"issue":"18","key":"1480_CR15","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693\u2013703.","journal-title":"N Engl J Med"},{"issue":"18","key":"1480_CR16","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1021\/jm2007613","volume":"54","author":"JJ Cui","year":"2011","unstructured":"Cui JJ, Tran-Dube M, Shen H, Nambu M, Kung PP, Pairish M, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011;54(18):6342\u201363.","journal-title":"J Med Chem"},{"issue":"2","key":"1480_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40264-018-0780-x","volume":"42","author":"A Puccini","year":"2019","unstructured":"Puccini A, Marin-Ramos NI, Bergamo F, Schirripa M, Lonardi S, Lenz HJ, et al. Safety and Tolerability of c-MET inhibitors in Cancer. Drug Saf. 2019;42(2):211\u201333.","journal-title":"Drug Saf"},{"issue":"25","key":"1480_CR18","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385\u201394.","journal-title":"N Engl J Med"},{"issue":"5","key":"1480_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1177\/1758834015590593","volume":"7","author":"BC Liao","year":"2015","unstructured":"Liao BC, Lin CC, Shih JY, Yang JC. Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol. 2015;7(5):274\u201390.","journal-title":"Ther Adv Med Oncol"},{"key":"1480_CR20","doi-asserted-by":"crossref","unstructured":"Yasuma T, Kobayashi T, D\u2019Alessandro-Gabazza CN, Fujimoto H, Ito K, Nishii Y et al. Renal Injury during Long-Term Crizotinib Therapy. Int J Mol Sci. 2018;19(10).","DOI":"10.3390\/ijms19102902"},{"issue":"9","key":"1480_CR21","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1634\/theoncologist.2014-0216","volume":"19","author":"SJ Klempner","year":"2014","unstructured":"Klempner SJ, Aubin G, Dash A, Ou SH. Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. Oncologist. 2014;19(9):1008\u201310.","journal-title":"Oncologist"},{"key":"1480_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.urology.2019.04.035","volume":"131","author":"CW Liaw","year":"2019","unstructured":"Liaw CW, Palese M, Fabrizio LD. A complex renal cyst in a patient on Crizotinib: Case Report. Urology. 2019;131:21\u20133.","journal-title":"Urology"},{"key":"1480_CR23","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.urology.2018.08.008","volume":"121","author":"K Okubo","year":"2018","unstructured":"Okubo K, Sato A, Nakamoto K, Hatanaka Y, Isono M, Hatanaka M, et al. Bosniak Category III renal cysts caused by Crizotinib in an anaplastic lymphoma kinase gene-rearranged Non-small Cell Lung Cancer patient. Urology. 2018;121:e3\u20134.","journal-title":"Urology"},{"issue":"6","key":"1480_CR24","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/cam4.437","volume":"4","author":"P Schnell","year":"2015","unstructured":"Schnell P, Bartlett CH, Solomon BJ, Tassell V, Shaw AT, de Pas T, et al. Complex renal cysts associated with crizotinib treatment. Cancer Med. 2015;4(6):887\u201396.","journal-title":"Cancer Med"},{"issue":"3\u20134","key":"1480_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000502664","volume":"104","author":"P Eiamprapaporn","year":"2020","unstructured":"Eiamprapaporn P, Mungwatthana N, Twinprai P, Sookprasert A, Chindaprasirt J, Ahooja A, et al. Crizotinib-Associated Renal cysts in anaplastic lymphoma kinase-positive Lung Cancer patients: a single-center experience. Urol Int. 2020;104(3\u20134):269\u201372.","journal-title":"Urol Int"},{"issue":"8925","key":"1480_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0140-6736(94)92344-2","volume":"344","author":"S Horie","year":"1994","unstructured":"Horie S, Higashihara E, Nutahara K, Mikami Y, Okubo A, Kano M, et al. Mediation of renal cyst formation by hepatocyte growth factor. Lancet. 1994;344(8925):789\u201391.","journal-title":"Lancet"},{"issue":"6 Pt 1","key":"1480_CR27","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1097\/01.ju.0000124263.51906.b9","volume":"171","author":"R Konda","year":"2004","unstructured":"Konda R, Sato H, Hatafuku F, Nozawa T, Ioritani N, Fujioka T. Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma. J Urol. 2004;171(6 Pt 1):2166\u201370.","journal-title":"J Urol"},{"key":"1480_CR28","doi-asserted-by":"publisher","first-page":"920990","DOI":"10.3389\/fonc.2022.920990","volume":"12","author":"Z Wan","year":"2022","unstructured":"Wan Z, Wang K, Yin X, Guo X, Cheng G, Pan J. Renal abscess caused by Crizotinib: a rare case report. Front Oncol. 2022;12:920990.","journal-title":"Front Oncol"},{"issue":"1","key":"1480_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000523737","volume":"15","author":"Y Amano","year":"2022","unstructured":"Amano Y, Kage H, Tanaka G, Sato Y, Tanaka M, Nagase T. Multiple brain metastases in a patient with ROS1 Fusion-positive lung adenocarcinoma as a Disease Flare due to Crizotinib Cessation caused by disseminated aseptic inflammation from Crizotinib-Associated Renal cysts: a Case Report. Case Rep Oncol. 2022;15(1):338\u201344.","journal-title":"Case Rep Oncol"},{"issue":"6","key":"1480_CR30","doi-asserted-by":"publisher","first-page":"e04278","DOI":"10.1002\/ccr3.4278","volume":"9","author":"NE Wiest","year":"2021","unstructured":"Wiest NE, Tzou KS, Olson MT, Herchko SM, Bajalia EM, Thiel DD, et al. Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with ALK-positive non-small-cell lung cancer: case report and review of the literature. Clin Case Rep. 2021;9(6):e04278.","journal-title":"Clin Case Rep"},{"issue":"12","key":"1480_CR31","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1007\/s00432-021-03664-w","volume":"147","author":"D Weber","year":"2021","unstructured":"Weber D, Decker M, Schuster M, Folz S, Sturmer CJ, Lutz MP. Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC. J Cancer Res Clin Oncol. 2021;147(12):3769\u201371.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1480_CR32","first-page":"89","volume":"13","author":"P Di Marino","year":"2020","unstructured":"Di Marino P, Mannetta G, Carella C, Grassadonia A, Tinari N, Natoli C, et al. Alectinib Induced regression of renal and hepatic cysts caused by Crizotinib. Int Med Case Rep J. 2020;13:89\u201393.","journal-title":"Int Med Case Rep J"},{"issue":"17","key":"1480_CR33","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2169\/internalmedicine.8445-16","volume":"56","author":"K Taima","year":"2017","unstructured":"Taima K, Tanaka H, Tanaka Y, Itoga M, Takanashi S, Tasaka S. Regression of Crizotinib-Associated Complex Cystic Lesions after switching to Alectinib. Intern Med. 2017;56(17):2321\u20134.","journal-title":"Intern Med"},{"issue":"1","key":"1480_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40644-017-0109-5","volume":"17","author":"LB Cameron","year":"2017","unstructured":"Cameron LB, Jiang DH, Moodie K, Mitchell C, Solomon B, Parameswaran BK. Crizotinib Associated Renal cysts [CARCs]: incidence and patterns of evolution. Cancer Imaging. 2017;17(1):7.","journal-title":"Cancer Imaging"},{"key":"1480_CR35","doi-asserted-by":"crossref","unstructured":"Ishida H, Ichikawa W, Sasaki Y. Crizotinib-induced pancreatic pseudocyst: a novel adverse event. BMJ Case Rep. 2015;2015.","DOI":"10.1136\/bcr-2015-211556"},{"issue":"3","key":"1480_CR36","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.radcr.2016.04.010","volume":"11","author":"WY Chan","year":"2016","unstructured":"Chan WY, Ang MK, Tan DS, Koh WL, Kwek JW. Imaging features of renal complications after crizotinib treatment for non-small-cell lung cancer: a case report. Radiol Case Rep. 2016;11(3):245\u20137.","journal-title":"Radiol Case Rep"},{"key":"1480_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clinimag.2020.03.011","volume":"65","author":"F Chen","year":"2020","unstructured":"Chen F, Patel NJ, Legout JD, Caserta MP. Development of complex renal cysts: a complication associated with crizotinib therapy. Clin Imaging. 2020;65:15\u20137.","journal-title":"Clin Imaging"},{"key":"1480_CR38","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1055\/s-0039-1689682","volume":"2","author":"G Suman","year":"2019","unstructured":"Suman G, Patra A, Janu A, Baheti A. Crizotinib-Associated Renal cystes: a case Series. J Gastrointest Abdom Radiol. 2019;2:130\u20134.","journal-title":"J Gastrointest Abdom Radiol"},{"issue":"4","key":"1480_CR39","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s13244-015-0417-x","volume":"6","author":"JB Jia","year":"2015","unstructured":"Jia JB, Lall C, Tirkes T, Gulati R, Lamba R, Goodwin SC. Chemotherapy-related complications in the kidneys and collecting system: an imaging perspective. Insights Imaging. 2015;6(4):479\u201387.","journal-title":"Insights Imaging"},{"issue":"2","key":"1480_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1148\/radiol.2362040218","volume":"236","author":"GM Israel","year":"2005","unstructured":"Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology. 2005;236(2):441\u201350.","journal-title":"Radiology"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-024-01480-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-024-01480-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-024-01480-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T11:02:01Z","timestamp":1713092521000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-024-01480-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,14]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1480"],"URL":"https:\/\/doi.org\/10.1186\/s13000-024-01480-7","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,14]]},"assertion":[{"value":"14 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from individual participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}